Baxter International Inc. (NYSE:BAX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. This clearance marks a significant advancement in infusion therapy technology and underscores Baxter’s commitment to innovation in healthcare.
The Novum IQ platform, which now includes both large volume and syringe infusion pumps, offers clinicians a single, integrated system across various patient care settings. Heather Knight, Executive Vice President and Group President of Medical Products and Therapies at Baxter, emphasized the platform’s customer-centric design and its potential to improve care delivery efficiency, safety, and decision-making.
The Novum IQ Infusion Platform is designed to address challenges faced by healthcare systems, including clinician turnover, burnout, and staffing shortages, while also prioritizing cost reduction and improved patient outcomes. Key features of the platform include a common user interface for LVP and SYR pumps, Dose IQ Safety Software with a customizable drug library and dose error reduction system, and the IQ Enterprise Connectivity Suite for enhanced EMR interoperability and cybersecurity.
The Novum IQ LVP and SYR pumps, along with their advanced software capabilities, aim to streamline infusion therapy processes, reduce cognitive burden, and provide additional safety measures for clinicians and patients. Baxter plans to further expand the platform through ongoing product development and regulatory submissions, reinforcing its commitment to delivering innovative solutions for healthcare providers.
